Exceptional Management and where to get viagra cheap Disruptive Products Top the cialis once daily Investment Checklist for Vista Partners' Ross Silver

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 20 May 2015 15:16

Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the canadian generic cialis time to dig out the viagra vs cialis vs levitra which is better value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and canadian pharmacy discount code viagra owns many of the stocks he writes about. In this interview with The Life Sciences Report, Silver puts two biotech names on the table for investors to consider.

 

Read more...
 

Fire Up the Immune System to Fight Cancers and brand cialis for sale Boost Portfolios: John McCamant

Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 13 May 2015 18:23

An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend.

Read more...
 

The Barbell Approach Builds Powerful Healthcare Stocks: StoneCastle's Bruce Campbell

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 07 May 2015 15:20

Portfolio manager Bruce Campbell wants the best of both worlds in his Canadian healthcare investments.

Read more...
 

How to Grow a Regenerative Medicine Industry in Canada: Michael May of CCRM

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 23 April 2015 12:38

There's a new kind of incubator in town. The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian nonprofit that fosters hands-on association between academia, government, industry and best price zithromax investors to grow stem cell and indian cialis generic regenerative medicine companies from the ground up. In this interview with The Life Sciences Report, 

Read more...
 

How to Profit from Australia's Healthiest Biotechs: Wilson HTM's Shane Storey

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 16 April 2015 12:51

Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets.

Read more...
 

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 09 April 2015 19:21

It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised patience.

Read more...
 

Why Biotech Investors Should Target the Takeouts: Cantor Fitzgerald's Irina Rivkind Koffler

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 02 April 2015 14:39
Taking a page out of Big Pharma's playbook—looking for likely takeout candidates—is a profitable way to approach small-cap biotechs as potential investments, especially since large caps with shrinking pipelines have an unquenchable hunger for good new drugs and buy now viagra technologies, and the resources to track those drugs and technologies down.
Read more...
 

Five Stocks Griffin Securities' Keith Markey Thinks Could Double or Triple

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 12 March 2015 12:50

For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and buy nexium online efficacy, there's just no betting on a biotech stock.

Read more...
 

How to Beat the Herd Mentality: Highline's Michael Higgins

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 26 February 2015 15:04
Michael Higgins of Highline Research Advisors believes it is absolutely vital for a sellside biotech analyst to understand what's going on outside the sector, because no stock lives on an island.
Read more...
 

Immuno-Oncology Promises Continued Wealth and female viagra 2012 Health: LifeTech Capital's Stephen Dunn

Print E-mail
By Staff - The Life Sciences Report   
Thursday, 19 February 2015 15:38

Immuno-oncology disabling cancer's defenses so that a patient's own immune system can seek it out and buy orlistat destroy it took center stage in the drug development world in 2014.

Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 51

Newsletter

BioMedReports Sunshine Heart Shares Sink Despite Rebooted Study; OXiGENE Announces Issuance of U.S. Patent for OXi4503: Belo... http://t.co/qTDdzXbHVO
5hreplyretweetfavorite
BioMedReports IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI): FDA Grants Fast Track Designation for Rexista Oxycodone XR ... http://t.co/C9Zlw8APDM
11hreplyretweetfavorite
BioMedReports Can you see what I hear? Blind human echolocators use visual areas of the brain http://t.co/T8K9sPdRPa